SCHEMBL32684875

SCHEMBL32684875

COC(=O)c1ccnc2ccc([C@@](C)(O)c3ncccc3F)cc12

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
PSMD14 O00487 1/20 0.40
ALOX15 P16050 1/20 0.39
HTT P42858 1/20 0.39
LMNA P02545 1/20 0.39
MAP2K1 Q02750 1/20 0.37
MET P08581 3/20 0.37
ACSS2 Q9NR19 2/20 0.36
TRPV1 Q8NER1 1/20 0.35
MEN1 O00255 1/20 0.35
PABPC1 P11940 1/20 0.35
KMT2A Q03164 1/20 0.35
EIF4H Q15056 1/20 0.35
SLC40A1 Q9NP59 1/20 0.35
PLA2G2A P14555 1/20 0.35
CYP11B2 P19099 1/20 0.35
KDM5A P29375 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31510539 1.00 KDM4E (0.41) KDM4EPSMD14ALOX15HTTLMNA
SCHEMBL30647611 0.88 LMNA (0.46) KDM4ELMNAACSS2KDM5A
SCHEMBL30647715 0.83 LMNA (0.48) KDM4EPSMD14ALOX15HTTLMNA
SCHEMBL26965962 0.83 LMNA (0.48) KDM4EPSMD14ALOX15HTTLMNA
SCHEMBL30647654 0.80 DYRK1B (0.41) KDM4EMETACSS2
SCHEMBL30647646 0.80 DYRK1B (0.41) KDM4EMETACSS2
SCHEMBL22492480 0.78 CFTR (0.54) KDM4EPSMD14LMNA
SCHEMBL26965991 0.77 LMNA (0.47) KDM4EPSMD14ALOX15HTTLMNA
SCHEMBL30647720 0.77 LMNA (0.47) KDM4EPSMD14ALOX15HTTLMNA
SCHEMBL22492342 0.74 PLA2G2A (0.54) KDM4EPSMD14LMNAMETPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070899-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2026-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070899-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES FAP, CTRL, CTSC KDM4E 2933/4885PSMD14 4709/4885ALOX15 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.